DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Return
12.76%
This Quarter Return
+18.6%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.69B
AUM Growth
+$682M
(+11%)
Cap. Flow
-$874M
Cap. Flow
% of AUM
-13.05%
Top 10 Holdings %
Top 10 Hldgs %
54.02%
Holding
681
New
246
Increased
85
Reduced
72
Closed
235
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$72.1M |
| 2 |
Indivior
INDV
|
$49.7M |
| 3 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$45.7M |
| 4 |
Merus
MRUS
|
$32.9M |
| 5 |
Viatris
VTRS
|
$30.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$102M |
| 2 |
Surgery Partners
SGRY
|
$94.4M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$57.6M |
| 4 |
BioNTech
BNTX
|
$49.8M |
| 5 |
Integra LifeSciences
IART
|
$42.8M |
Sector Composition
| 1 | Healthcare | 87.45% |
| 2 | Industrials | 0.72% |
| 3 | Technology | 0.55% |
| 4 | Financials | 0.42% |
| 5 | Consumer Discretionary | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
BellRing Brands
BRBR
$4.97B
| $682K | 0.01% |
11,235
+418
| +4% | +$25.4K |
|
227
Edwards Lifesciences
EW
$47.5B
| $682K | 0.01% |
+10,332
| New | +$682K |
|
228
Cytokinetics
CYTK
$6.34B
| $680K | 0.01% |
12,884
+8,518
| +195% | +$450K |
|
229
Spirit AeroSystems
SPR
$4.8B
| $680K | 0.01% |
20,923
+10,340
| +98% | +$336K |
|
230
Biogen
BIIB
$20.6B
| $679K | 0.01% |
3,504
+2,573
| +276% | +$499K |
|
|
PARA
231
DELISTED
Paramount Global Class B
PARA
| $664K | 0.01% |
+62,516
| New | +$664K |
|
232
Trimble
TRMB
$19.2B
| $664K | 0.01% |
+10,689
| New | +$664K |
|
233
Carlyle Group
CG
$23.1B
| $660K | 0.01% |
+15,332
| New | +$660K |
|
234
Procept Biorobotics
PRCT
$2.26B
| $656K | 0.01% |
8,190
-236
| -3% | -$18.9K |
|
235
BioMarin Pharmaceuticals
BMRN
$11.1B
| $651K | 0.01% |
9,255
-577
| -6% | -$40.6K |
|
236
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$71.3M
| $650K | 0.01% |
92,787
| – | – |
|
237
Saic
SAIC
$4.83B
| $648K | 0.01% |
4,650
-4,261
| -48% | -$593K |
|
238
Elanco Animal Health
ELAN
$9.16B
| $634K | 0.01% |
+43,127
| New | +$634K |
|
239
Mastercard
MA
$528B
| $632K | 0.01% |
+1,280
| New | +$632K |
|
240
Emergent Biosolutions
EBS
$404M
| $632K | 0.01% |
+75,642
| New | +$632K |
|
241
Morgan Stanley
MS
$236B
| $631K | 0.01% |
+6,049
| New | +$631K |
|
242
EverQuote
EVER
$860M
| $627K | 0.01% |
+29,712
| New | +$627K |
|
243
Harrow
HROW
$1.37B
| $623K | 0.01% |
13,863
-11,584
| -46% | -$521K |
|
244
Zymeworks
ZYME
$1.14B
| $622K | 0.01% |
+49,546
| New | +$622K |
|
245
Hanesbrands
HBI
$2.27B
| $612K | 0.01% |
+83,238
| New | +$612K |
|
246
BlackLine
BL
$3.32B
| $611K | 0.01% |
11,079
+2,209
| +25% | +$122K |
|
247
Vital Energy
VTLE
$635M
| $610K | 0.01% |
+22,667
| New | +$610K |
|
248
Riot Platforms
RIOT
$4.91B
| $609K | 0.01% |
82,063
+58,731
| +252% | +$436K |
|
249
ZimVie
ZIMV
$532M
| $608K | 0.01% |
+38,329
| New | +$608K |
|
250
MKS Inc. Common Stock
MKSI
$7.02B
| $602K | 0.01% |
+5,541
| New | +$602K |
|